Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.
By
By Kara Nyberg, PhD Posted: June 24, 2020 An exploratory analysis of circulating free DNA (cfDNA) shows that lorlatinib confers potent antitumor activity in pretreated patients with ALK-positive NSCLC regardless […]
View ILCN Archives
Provider Resources
INDUSTRY SUPPORTED